Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints
Go back to Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints| (NASDAQ: NERV) | Delayed: 4.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.92 | 52 Week High | $15.84 | |||
| Open | $4.92 | 52 Week Low | $3.45 | |||
| Day High | $4.92 | P/E | N/A | |||
| Day Low | $4.92 | EPS | $0.00 | |||
| Volume | 1 | |||||
